CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 172 enrolled
Drug / intervention
Rocuronium +2 moredrug
Likely dose
Rocuronium 0.6 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06225466
NCT06225466Phase 4Completed

Anesthesia With Neuromuscular Blockade and Reversal With Sugammadex Compared to Anesthesia Without Muscle Relaxation During Pediatric High-Risk Adenotonsillectomy: A Randomized-Controlled Trial

University of Texas Southwestern Medical Center·interventional·Posted Jan 26, 2024·Updated Jul 28, 2025

In Brief

A Phase 4 clinical trial evaluating Rocuronium, Sugammadex, and 1 other intervention for Tonsillectomy. Completed, enrolled 172 participants across 1 site.

Detailed Summary

The goal of this clinical trial is to compare general anesthesia with muscle relaxation and reversal of the relaxation at the end of surgery or without muscle relaxation in high-risk children having adenotonsillectomy surgery. The main questions it aims to answer are: 1. What is the impact of general anesthesia with muscle relaxation on opioid pain medication requirements during and after adenotonsillectomy? 2. What is the impact of general anesthesia with muscle relaxation on postoperative breathing complications and the adequacy of postoperative lung air volumes during breathing? Participants will wear three additional, noninvasive monitors during surgery, and one additional monitor after surgery. The amount of opioid pain medication required will be tracked, and the patient will be observed postoperatively for breathing complications. Measurements will be collected from the monitor worn postoperatively. Researchers will compare general anesthesia with muscle relaxation and reversal of relaxation at the end of surgery with general anesthesia without muscle relaxation to test the hypothesis that the approach using muscle relaxation reduces the amount of opioid pain medication required during and after surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTonsillectomy
CountriesUnited States

Timeline

Phase 4CompletedFinished
202420252026
First PostedJan 26, 2024
Enrollment StartApr 10, 2024
Primary CompletionSep 27, 2024
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 2.4 years ago

Interventions

Rocuroniumdrug

After induction of anesthesia and placement of an IV, rocuronium 0.6 mg/kg (maximum dose 50mg) will be administered. Additional doses of rocuronium 0.2 mg/kg (maximum dose 15 mg) will be administered when the neuromuscular transmission monitor indicates a train of four count of 2 or greater.

Sugammadexdrug

When the surgery is completed, sugammadex 2 mg/kg will be administered if the neuromuscular transmission monitor indicates the train of four count is 2 or greater. Sugammadex 4 mg/kg will be administered if 1) the train of four count is 1, or 2) if the train of four count is 0 and the post tetanic count is at least 1. There is no maximum dose of sugammadex.

Anesthesia without neuromuscular blockadeother

Anesthesia without rocuronium or sugammadex